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Abstract: Background: Antiretroviral therapy (ART) is the cornerstone of HIV clinical care and is increasingly 
recognized as a key component of HIV prevention. However, the benefits of ART can be realized only if HIV-infected 
persons maintain high levels of adherence. 
Methods: We present interview data (collected from June 2007 through September 2008) from a national HIV 
surveillance system in the United States—the Medical Monitoring Project (MMP)—to describe persons taking ART. We 
used multivariate logistic regression to assess behavioral, sociodemographic, and medication regimen factors associated 
with three measures that capture different dimensions of nonadherence to ART: dose, schedule, and instruction. 
Results: The use of ART among HIV-infected adults in care was high (85%), but adherence to ART was suboptimal and 
varied across the three measures of nonadherence. Of MMP participants currently taking ART, the following reported 
nonadherence during the past 48 hours: 13% to dose, 27% to schedule, and 30% to instruction. The determinants of the 
three measures also varied, although younger age and binge drinking were associated with all aspects of nonadherence. 
Conclusion: Our results support the measurement of multiple dimensions of medication-taking behavior in order to avoid 
overestimating adherence to ART. 
Keywords: HIV, medication adherence, antiretroviral therapy, Centers for Disease Control and Prevention (U.S.). 
INTRODUCTION 
 A high level of adherence to antiretroviral therapy (ART) 
is necessary to maintain viral suppression and achieve 
optimal clinical outcomes for HIV-infected persons [1, 2], 
though there is little consensus on the minimum threshold of 
adherence needed for virologic suppression [3, 4]. 
Medication adherence often accompanies other healthy 
behaviors such as diet and health care utilization [5]. ART 
may also improve population health, reduce the number of 
premature deaths, and lower health care costs, as studies 
indicate that access and adherence to ART may play an 
important role in reducing HIV transmission by suppressing 
HIV viral load (VL) [6, 7]. Successful ART requires 
clinicians to assess the risks of nonadherence before deciding 
on a regimen and to accurately monitor and support 
adherence throughout therapy [8, 9]. 
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 Clinical outcomes have been better predicted by 
measuring multiple dimensions of medication-taking 
behaviors than by measuring missed doses [10]. Gill and 
colleagues found the timing of doses to be important for VL 
suppression [11]. Despite these findings, many studies of 
ART adherence have been focused on missed doses, not on 
adherence to medication schedules and special instructions 
such as dietary restrictions. Failure to inquire about 
adherence to schedule and instruction may lead to inaccurate 
estimates of a patient’s level of adherence and may thus 
result in missed opportunities to educate or failure to identify 
nonadherence as a cause of treatment failure. The few 
studies that have compared different dimensions of 
nonadherence have found that their predictors vary [12, 13]. 
Because multiple measures of nonadherence have proved 
useful in predicting clinical outcomes and our knowledge of 
their predictors (and how they may vary across measures) is 
limited, examination of multiple measures is warranted. 
Better knowledge of these factors may inform the 
development of interventions to improve all aspects of 
adherence. 
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 The primary objective of our analysis was to describe the 
use of ART and to assess the various measures of ART 
nonadherence in a national sample of adult HIV patients. A 
secondary objective was to explore the factors associated 
with the various dimensions of medication-taking behavior, 
which have been incompletely described to date. 
METHODS 
 We performed a cross-sectional analysis of data from the 
Medical Monitoring Project (MMP), a supplemental 
surveillance system for collecting clinical and behavioral 
data on HIV-infected adults receiving care. The methods 
have been described in detail elsewhere [14, 15]. MMP uses 
a three-stage sampling design to obtain annual cross-
sectional probability samples of HIV-infected adults in care. 
In the first stage, states are selected to participate, then HIV 
care facilities in these states are sampled, and finally HIV-
infected adults in care at participating facilities are sampled. 
Face-to-face interviews are conducted to collect information 
on demographics, adherence to HIV medication regimens, 
and behavioral risk factors. The data were collected in 19 
states and Puerto Rico from June 2007 through September 
2008.
1
 The Centers for Disease Control and Prevention has 
determined that MMP is not human subjects research 
because it is a routine disease surveillance activity. However, 
participating project areas obtain local Institutional Review 
Board (IRB) approval to conduct MMP as required locally. 
We asked participants about their medication-taking 
behaviors during the 48 hours before interview. Dose 
nonadherence refers to failure to take a prescribed dose or 
set of pills/spoonfuls/injections of antiretroviral (ARV) 
medications. Schedule nonadherence refers to failure to 
follow the prescribed schedule for ARV medications, such as 
“2 times a day” or “every 8 hours.” Instruction 
nonadherence refers to failure to follow special instructions 
accompanying ARV medication prescriptions, such as “take 
with food” or “take on an empty stomach.” Instruction 
nonadherence was asked of only the participants who 
reported having received special instructions for their ARV 
medications. Although self-reported measures have generally 
been found to indicate lower nonadherence than other 
measures (such as pill counts, Medication Event Monitoring 
System [MEMS] devices, or pharmacy refill records), no 
standard exists for measuring nonadherence [16] and self-
reported measures have been correlated with clinical 
outcomes such as VL [17]. We defined nonadherence as 
failure to take ARV medication exactly as prescribed (i.e., 
100% of doses taken for dose adherence, 100% of doses on 
the prescribed schedule for schedule adherence, and 100% 
instructions followed for instruction adherence) given that 
100% adherence is a common threshold for self-reported 
measures [18]. 
 After determining the frequencies of selected 
characteristics to describe participants currently taking ART 
and those not taking ART, we tested for differences in these 
characteristics by using chi-square tests. To assess whether 
                                                           
1The 26 participating project areas: California, Chicago (Illinois), Delaware, 
Florida, Georgia, Houston (Texas), Illinois, Indiana, Los Angeles County 
(California), Maryland, Massachusetts, Michigan, Mississippi, New Jersey, 
New York, New York City (New York), North Carolina, Oregon, 
Pennsylvania, Philadelphia (Pennsylvania), Puerto Rico, San Francisco 
(California), South Carolina, Texas, Virginia, and Washington. 
our measures of nonadherence are related to clinical 
outcomes, we then tested for bivariate associations between 
each of the three measures of nonadherence and self-reported 
undetectable VL, using the Mantel-Haenszel chi-square test 
and binomial logistic regression. In addition, we used these 
methods to examine the relationship between the total 
number of reported nonadherence measures (measured as 0 = 
100% adherent on all three measures, 1 = nonadherent on 
one measure, 2 = nonadherent on two measures, 3 = 
nonadherent on all three measures) and self-reported 
undetectable VL. 
 Finally, to explore differences in the factors associated 
with the measures of nonadherence, we tested for bivariate 
relationships between dose, schedule, and instruction 
nonadherence and the factors associated with nonadherence 
in the scientific literature. Factors associated with each 
measure of nonadherence (significant at the p < 0.10 level) 
were included in three multivariate regression models. Final 
models were determined by using backward stepwise 
regression with a p < 0.05 retention criterion. Model fit was 
assessed by using the Hosmer and Lemeshow goodness-of-
fit test. 
 All independent variables refer to the past 12 months 
except where otherwise noted. The following independent 
variables were examined for each of the three models: 
 Sociodemographic: gender, age at interview, 
race/ethnicity, educational attainment (<high school, 
>high school or equivalent), receipt of public 
assistance, homelessness (defined as living on the 
street, in a shelter, a single-room-occupancy hotel, 
temporarily staying with friends/family, or living in a 
car), lack of continuous health insurance coverage 
 Alcohol and drug use: crack use, amphetamine use, 
binge drinking in the past 30 days (>4 drinks per day 
for men, >3 drinks per day for women) 
 Mental health: feeling downhearted and depressed in 
past 4 weeks (5-point Likert scale ranging from 1 = 
“none of the time” to 5 = “all of the time”) 
 HIV-related: not knowing most recent VL test result, 
number of daily ARV doses (defined as a set of 
pills/spoonfuls/injections of antiretroviral (ARV) 
medications), years since HIV diagnosis, having a 
discussion with a provider about ARV drug resistance 
RESULTS 
 All sampled states and territories agreed to participate in 
MMP. During January-April 2007, a sample of 10,503 
patients was selected from 582 participating HIV care 
facilities in the 26 participating project areas. The overall 
median facility participation rate was 91.4% (range across 
project areas, 65% to 100%). Of the sample, 311 were 
ineligible, resulting in a total of 10,192 patients. Reasons for 
ineligibility included: 29 duplicates, 18 less than 18 years of 
age, 63 HIV-negative, 114 no care during the sample 
selection period, and 87 ineligible for other reasons. The 
median patient participation rate was 40% (range across 
project areas, 3% to 76%). A total of 3,944 standard 
interviews were conducted from June 2007 through 
September 2008. For this analysis, the data of 43 participants  
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Table 1. Factors associated with current use of ART–United States, Medical Monitoring Project, 2007-2008 
 
    
Chi-Square Test 
for Differences    
Currently 
Taking ART 
(n = 3307) 
  
Not Currently 
Taking ART  
(n = 579) 
  (p Value)  













Female 830 25 197 34 (<.0001) 













25-34 280 8 101 17 (<.0001) 
35-44 1039 31 214 37   
45-54 1311 40 180 31   













Hispanic 663 20 95 16 (<.0001) 
White, non-Hispanic 1173 35 156 27   
Other  212 6 39 7   
Education 











> High School or equivalent 2576 78 430 74 (0.05) 












Yes 1667 50 256 44 (0.01) 












Yes 808 24 197 34 (<.0001) 












Yes 227 7 79 14 (<.0001) 
Years since HIV diagnosis 











2-5 616 19 189 33 (<.0001) 
6-10 764 23 127 22   
11-25 1711 52 226 39   












Yes 2587 78 383 66 (<.0001) 












Detectable but <5000 307 9 93 16 (<.0001) 
>5000-<100000 166 5 142 25   
>100000 58 2 38 7   
Missing 720 22 196 34   
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were excluded because interviewers were not confident of 
the validity of the responses (for example, cases where the 
participant was incoherent or unresponsive to interview 
questions). 
Antiretroviral Therapy Use 
 Of 3886 participants who provided information about 
ART, 3307 (85%) were currently taking ART. Roughly 
equal proportions had never taken ART (8%) or had 
previously taken ART (7%). Compared to those not 
currently taking ART, those who were currently taking ART 
were significantly more likely to be male, older, non-
Hispanic white (hereafter referred to as white) or Hispanic, 
HIV-diagnosed for a longer period of time, and not 
homeless; to have continuous healthcare coverage for the 
past year and a lower self-reported nadir CD4+ T-
lymphocyte (CD4) count; to report a lower VL and feeling 
downhearted and depressed (hereafter referred to as 
depressed) less often; to know the result of their most recent 
VL test; and not to receive public assistance, not to use crack 
or amphetamines, and not to binge drink (Table 1). 
Nonadherence to Antiretroviral Therapy 
 Table 2 presents descriptive statistics for participants 
who reported nonadherence during the past 48 hours. Of  
 
MMP participants currently taking ART, 13% reported 
nonadherence to dose, 27% to schedule, and 30% to 
instruction. Considering all measures, nonadherence was 
reported by 38% of participants: 22% reported nonadherence 
to one measure, 11% to two measures, and 5% to all three 
measures. 
Association between Self-reported Detectable Viral Load 
and Nonadherence 
 Participants were asked about the results of their most 
recent VL test (see Table 2). Tests of association revealed 
statistically significant positive relationships between 
nonadherence and detectable VL test result (p < 0.0001 for 
dose and schedule nonadherence and p = 0.03 for instruction 
nonadherence). In addition, there was a significant and 
positive association between the number of nonadherence 
measures reported and detectable VL (p < 0.0001). Logistic 
regression modeling results indicated that the odds of a 
detectable VL more than doubled for those reporting dose 
nonadherence (odds ratio [OR], 2.2; 95% confidence interval 
[CI], 1.7-2.8). Similar analyses yielded an OR of 2.1 for 
schedule nonadherence (CI, 1.7-2.6) and 1.3 for instruction 
nonadherence (CI, 1.0-1.7). In addition, nonadherence to 
multiple measures was associated with increased odds of a 
detectable VL. In a comparison of participants who reported 
nonadherence and participants who did not, the odds of  
 
(Table 1) contd….. 
    
Chi-Square Test 
for Differences    
Currently 
Taking ART 
(n = 3307) 
  
Not Currently 
Taking ART  
(n = 579) 
  (p Value)  
Characteristic No.  % of Total No.  % of Total   












200-349 642 19 128 22 (<.0001) 
350-499 261 8 112 19   
500+ 140 4 102 18   
Missing 753 23 147 25   
Feeling downhearted and depressed, past 4 weeks 











Most of the time 315 10 77 13 (0.00) 
Some of the time 992 30 155 27   
A little of the time 799 24 153 26   
None of the time 1054 32 154 27   












Yes 167 5 56 10 (<.0001) 












Yes 152 5 40 7 (0.02) 












Yes 426 13 116 20 (<.0001) 
Note: ART, antiretroviral therapy; values may not sum to total due to missing data; missing values shown when >10% of total. 
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   Instruction
c
  Currently  
Taking  
ART  Nonadherence  Nonadherence  Nonadherence  
  
n = 3307  n = 444 
Chi-Square  
Test for  
Differences  
(p Value)  
n = 893  
Chi-Square  
Test for  
Differences  
(p Value)  
n = 638  
Chi-Square  
Test for  
Differences  
(p Value)  
Characteristic No.  % No.  %  No.  %  No.  %  
Gender            
   Male 2431 74 293 66 15.62 591 66 34.68 462 72 1.60 
   Female 830 25 145 33 (0.00) 289 32 (<.0001) 167 26 (0.45) 
   Transgender  45 1 6 1  13 1  9 1  
Age (years)            
   18-24 45 1 18 4 11.33 21 2 12.48 17 3 25.85 
   25-34 280 8 43 10 (0.00) 83 9 (0.00) 68 11 (<.0001) 
   35-44 1039 31 135 30  300 34  226 35  
   45-54 1311 40 182 41  340 38  245 38  
   <55 632 19 66 15  149 17  82 13  
Race/ethnicity            
Black, non-Hispanic 1254 38 208 47 33.14 400 45 64.78 243 38 0.86 
Hispanic 663 20 102 23 (<.0001) 219 25 (<.0001) 146 23 (0.83) 
White, non-Hispanic 1173 36 105 24  230 26  207 32  
Other  212 6 29 7  44 5  42 7  
Education            
< High School 729 22 111 25 2.68 250 28 25.41 149 23 0.88 
> High School or equivalent 2576 78 332 75 (0.10) 643 72 (<.0001) 488 77 (0.35) 
Public assistance,  
past 12 months 
           
No  1639 50 184 41 13.58 380 43 23.85 323 51 0.03 
Yes 1667 50 260 59 (0.00) 513 57 (<.0001) 315 49 (0.86) 
Lapse in health coverage,  
past 12 months 
           
No 2491 76 327 74 0.64 671 75 0.04 453 71 0.94 
Yes 808 24 115 26 (0.42) 220 25 (0.84) 185 29 (0.33) 
Homeless, past 12 months            
No 3080 93 398 90 9.81 808 90 13.63 581 91 3.47 
Yes 227 7 46 10 (0.00) 85 10 (0.00) 57 9 (0.06) 
Years since HIV diagnosis            
< 1  18 1 <5  <1 6.29 <5  <1 4.00 <5  1 1.03 
2-5 616 20 69 17 (0.01) 140 17 (0.05) 131 22 (0.31) 
6-10 764 25 93 22  219 26  147 25  
11-25 1711 55 254 61  467 56  315 53  
Knew most recent HIV viral load  
test result 
           
     No 639 20 108 25 8.14 238 27 44.22 104 17 2.25 
Yes 2587 80 326 75 (0.00) 629 73 (<.0001) 513 83 (0.13) 
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detectable VL was 1.3 times as high (CI, 1.0-1.7) for those 
who reported nonadherence to one measure, 2.1 times as 
high (CI, 1.6-2.8) for those who reported nonadherence to 
two measures, and 2.9 times as high (CI, 2.0-4.1) for those 
who reported nonadherence to all three measures. 
Factors Associated with Each Measure of Nonadherence 
 The factors independently associated with dose 
nonadherence were female gender; per year decrease in age; 
non-Hispanic black (hereafter referred to as black) and  
 
Hispanic race/ethnicity; receipt of public assistance; feeling 
depressed all, most, or some of the time; crack use; binge 
drinking; higher number of years since HIV diagnosis; and 
higher number of daily ARV doses (Table 3). The factors 
independently associated with schedule nonadherence were 
female gender, per year decrease in age, black and Hispanic 
race/ethnicity, less than high school education, 
homelessness, receipt of public assistance, binge drinking, 
higher number of daily ARV doses, and not knowing one’s 
most recent VL test result. The factors independently  
 





   Instruction
c
  Currently  
Taking  
ART  Nonadherence  Nonadherence  Nonadherence  
  
n = 3307  n = 444 
Chi-Square  
Test for  
Differences  
(p Value)  
n = 893  
Chi-Square  
Test for  
Differences  
(p Value)  
n = 638  
Chi-Square  
Test for  
Differences  
(p Value)  
Characteristic No.  % No.  %  No.  %  No.  %  
Most recent HIV viral load test  
result 
           
Undetectable 2056 62 218 49 44.11 438 49 49.47 384 60 4.48 
Detectable but <5000 307 9 54 12 (<.0001) 104 12 (<.0001) 73 11 (0.03) 
>5000-<100000 166 5 36 8  61 7  41 6  
>100000 58 2 18 4  26 3  15 2  
Missing 720 22 118 27  264 30  125 20  
Feeling downhearted and  
depressed, past 4 weeks 
           
    All of the time 140 4 36 8 29.39 39 4 12.11 32 5 14.15 
Most of the time 315 10 56 13 (<.0001) 104 12 (0.00) 67 11 (0.00) 
Some of the time 992 30 143 32  287 32  212 33  
A little of the time 799 24 97 22  215 24  165 26  
None of the time 1054 32 110 25  245 28  158 25  
Crack use, past 12 months            
No 3128 95 403 91 18.36 829 93 8.00 597 94 4.69 
Yes 167 5 41 9 (<.0001) 61 7 (0.00) 39 6 (0.03) 
Amphetamine use,  
past 12 months 
           
No 3142 95 418 94 1.72 842 95 0.74 601 95 3.30 
Yes 152 5 26 6 (0.19) 46 5 (0.39) 34 5 (0.07) 
Binge drinking, past 30 days            
No 2864 87 359 81 16.42 745 84 11.41 519 82 29.95 
Yes 426 13 84 19 (<.0001) 144 16 (0.00) 115 18 (<.0001) 
Discussed resistance with  
provider, past 12 months 
           
   No 1174 36 128 29 10.12 310 35 0.24 197 31 0.33 
   Yes 2079 64 309 71 (0.00) 567 65 (0.62) 431 69 (0.56) 
Note: ART, antiretroviral therapy; values may not sum to total due to missing data; missing values shown when >10% of total. 
aDose nonadherence refers to not taking a dose or set of pills/spoonfuls/injections of ARV medications.  
bSchedule nonadherence refers to not following a specific schedule for ARV medication, such as “2 times a day” or “every 8 hours.”  
cInstruction nonadherence refers to not following special instructions for ARV medication, such as “take with food” or “take on an empty stomach.” Dietary instruction adherence is 
only calculated for those participants reporting having special instructions for their ARV medications. 
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Table 3. Logistic Regression Models of Factors Associated with Nonadherence to ART During the Past 48 Hours–United States, 










(N = 3307)  (N = 3298)  (N = 2101) 
Characteristic  
OR  
(95% CI)  
aOR  
(95% CI)  
OR  
(95% CI)  
aOR  
(95% CI)  
OR  
(95% CI)  
aOR  
(95% CI)  
Gender              
  Male  Ref  Ref  Ref  Ref      









NS   























Race/ethnicity            









    









NS   
  White, non-Hispanic  Ref  Ref  Ref  Ref      









    
Education              
  < high school  NS   Ref  Ref  NS   





    
Homeless, past 12 months             
  No  Ref  -  Ref  Ref  Ref  -  











Public assistance, past 12 
months 
            
  No  Ref  Ref  Ref  Ref  NS   









    
Feeling downhearted and 
depressed, past 4 weeks 
            
















































  None of the time  Ref  Ref  Ref  -  Ref  Ref  
Crack use, past 12 months             
  No  Ref  Ref  Ref  -  Ref  -  
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associated with instruction nonadherence were per year 
decrease in age; feeling depressed most, some, or a little of 
the time; and binge drinking. 
DISCUSSION 
 Although studies on nonadherence to ART are common, 
one strength of this analysis is the use of probability 
sampling methods, which resulted in coverage of patients 
from 582 medical facilities in 19 U.S. states and Puerto Rico. 
The use of ART was high among adults in care for HIV. The 
persons not receiving ART were more likely to be female, to 
be black, and to report a lapse in health coverage, substance 
use, higher VL results, higher CD4 count as the nadir, and 
more frequent feelings of depression. Our findings agree 
with those in other reports [19-25]. Understanding factors 
associated with use of ART may inform efforts to increase 
appropriate ART among HIV-infected persons. 
 Nonadherence to ART was substantial. Reported 
nonadherence during the past 48 hours ranged from 13% to 
30%, depending on which measure was examined; 38% were 
nonadherent to at least one measure. We found a direct 
relationship between a detectable VL and each of the three 
measures of nonadherence. The association increased with 
the number of measures to which a patient was nonadherent, 
indicating the clinical importance of assessing multiple 
dimensions of nonadherence. Our findings are consistent 
with those reported previously [10, 11], but there have been 
few studies comparing dose, schedule, and instruction 
nonadherence, so further examination of the impact of 
different measures of nonadherence on clinical outcomes is 
warranted. 
 Although predictors of the three measures of 
nonadherence varied, younger age and binge drinking were 
consistently associated with poorer adherence. Like other 
researchers [26], we found associations between younger age 
and multiple measures of nonadherence. Lifestyle 
differences, decreased awareness of mortality and thus 
motivation to care for one’s health, and a survivor effect 
have been proposed as reasons for poorer adherence among 
younger HIV-infected persons [27]. Measured in various 
ways, alcohol use has consistently been associated with 
nonadherence [28, 29]. We found that binge drinking was 









(N = 3307)  (N = 3298)  (N = 2101) 











Amphetamine use, past 12 
months 
            
  No  NS   NS   Ref  -  




Binge drinking, past 30 days              
  No  Ref  Ref  Ref  Ref  Ref  Ref  































NS   
Knew most recent HIV viral 
load test result 
            








NS   
  Yes  Ref  -  Ref  Ref      
Discussed resistance with 
provider, past 12 months 
            
  No  Ref  -  NS   NS   
  Yes  
1.43  
(1.15-1.78)  
-          
Note: ART, antiretroviral therapy; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; Ref, reference category; NS, not significant. 
a Dose nonadherence refers to not taking a dose or set of pills/spoonfuls/injections of ARV medications.  
b Schedule nonadherence refers to not following a specific schedule for ARV medication, such as “2 times a day” or “every 8 hours.”  
c Instruction nonadherence refers to not following special instructions for ARV medication, such as “take with food” or “take on an empty stomach.” Dietary instruction adherence is 
only calculated for those participants reporting having special instructions for their ARV medications. 
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strongly associated with all three measures of nonadherence. 
Others have found that the quantity of alcohol ingested was 
more important in predicting nonadherence than was the 
frequency of use [29, 30]. Taken together, these findings 
suggest that HIV care providers should ask patients about 
both the frequency and the quantity of alcohol consumed. 
When a patient acknowledges binge drinking, the provider 
should explain how binge drinking affects ART adherence 
and other health behaviors. Such conversations could help 
HIV care providers identify patients who need more 
intensive counseling about adherence and substance use. 
Few effective interventions have addressed problem drinking 
among HIV-infected persons [31], and the effects of the 
small number of trials on adherence among problem drinkers 
have not been sustained [32, 33]. The limited evidence 
suggests that adapting adherence interventions to persons 
with alcohol problems may be challenging [31]. Our results 
underscore the need to develop effective adherence 
interventions for problem drinkers, which potentially could 
have positive effects on all aspects of adherence. 
 Black and Hispanic race/ethnicity, female gender, receipt 
of public assistance, feeling depressed, and number of daily 
ARV doses were also independently associated with poorer 
adherence for at least two of the three measures of 
nonadherence. Several recent studies have found that 
race/ethnicity is independently associated with nonadherence 
[17, 34, 35]. Race/ethnicity may also be a proxy for factors 
associated with nonadherence, such as differences in trust of 
physicians [36] or HIV conspiracy beliefs (e.g., the belief 
that HIV was created by the U.S. government to perpetrate 
genocide against blacks) [37]. Recent studies indicate that 
disparities in health literacy and numeracy skills, which we 
were not able to measure, may also be important mediators 
of the relationship between race and medication management 
[38, 39]. 
 Similar to findings regarding adherence to treatment for 
chronic diseases such as diabetes [40], published 
descriptions of the effect of gender on ART adherence in the 
scientific literature have been mixed; some studies find 
women more likely to be nonadherent [41, 42], and others 
find no difference by gender [43]. Our finding suggests 
gender may influence some, but not all, dimensions of 
medication-taking behavior (dose and schedule 
nonadherence, but not instruction nonadherence). Another 
possible explanation for the observed gender differences is 
that other factors affecting nonadherence, such as alcohol or 
drug use, may differ for men and women [44]. Additional 
factors we were not able to measure, such as numeracy skills 
[45], may also mediate the relationship between gender and 
nonadherence. 
 Our finding that the frequency of feelings of depression 
was associated with dose and instruction nonadherence to 
ART is consistent with other studies [46, 47]. This 
association reinforces the importance of active screening for 
depression among HIV-infected persons [48]. Studies have 
suggested that training in stress management [49] and 
prescription of antidepressant medications [50] may improve 
adherence in this population. 
 Our finding that nonadherence increases as the daily 
ARV dose increases agrees with published results [51, 52]. 
Airoldi and colleagues found that switching to a single-pill 
regimen improved adherence [53]. Although some ART 
regimens are less susceptible to nonadherence than others 
[9], our findings suggest that simplifying ART regimens by 
decreasing dosing frequency would improve adherence. 
LIMITATIONS 
 Although MMP uses population-based sampling 
methods, due to low patient response rates across data 
collection sites MMP data are not weighted and thus are not 
representative of HIV-infected patients in care in the United 
States. However, probability sampling is advantageous even 
with low response rates because of the value of unbiased 
sampling from well-defined populations [54]. States with the 
lowest patient response rates were not substantially different 
by region or HIV epidemiology from those with higher 
response rates. Examination of the patient sampling frame 
indicates that respondents and nonrespondents did not differ 
by gender. Participants were slightly older than 
nonparticipants, and African Americans were somewhat 
underrepresented. Because we found that younger age and 
black race are associated with higher nonadherence, as have 
other studies [17, 26, 34, 35], these relationships may in fact 
be stronger than those found for our sample. Despite low 
patient response, the response rates at the project area and 
facility stages of sampling were high, and the size and 
breadth of our facility and patient samples are notable. 
 Because we studied self-reported measures, our findings 
are subject to the limitations of self-reported information, 
such as recall and social desirability biases. Because self-
reported measures of adherence have underestimated the 
extent of nonadherence [16, 18], our estimates of 
nonadherence may in fact be lower than actual levels of 
nonadherence. In addition, we were not able to verify 
through medical record review self-reported clinical 
information such as receipt of ART. However, Wood and 
colleagues found relatively high correspondence between 
self-reported and medical record documentation of current 
use of ART [55], leading us to have confidence in our 
results. Also, our analysis was restricted to self-reported VL, 
and the number of missing responses was high because of 
difficulties with recall. However, for undetectable VL 
results, the reported agreement between self-report and the 
medical record has been relatively high [56, 57]. Also, as our 
data showed a positive association between dose and 
schedule nonadherence and not knowing one’s most recent 
VL, it is unlikely that missing data would account for the 
relationship found between higher VL and the number of 
nonadherence measures reported. 
 Our analysis of use of ART is limited due to lack of 
comprehensive clinical information that would allow us to 
determine need for therapy among those not on ART. Use of 
self-reported CD4 values to indicate need for ART is 
insufficient because other clinical factors are also relevant to 
treatment decisions (e.g. Hepatitis B coinfection, HIV-
associated nephropathy). In addition, because recent 
treatment guidelines [8] suggest that ART should be an 
option for all patients regardless of CD4, we felt it was 
important to describe the difference between those on and 
not on ART for the entire sample. 
 Our logistic regression models regarding nonadherence 
to instruction included only the participants who had 
222    The Open AIDS Journal, 2012, Volume 6 Beer et al. 
received special instructions. However, limiting our analysis 
of the dose and schedule nonadherence models to those who 
received special instructions would have introduced bias by 
restricting the population to those whose regimens require 
special instructions. To ensure that our findings were not due 
to differences in the participants included in the models, we 
ran the dose and schedule models, restricting them to 
participants who have received special instructions: we did 
not find substantive differences compared with results that 
included all respondents. 
CONCLUSION 
 Recent guidelines recommend initiation early in the 
course of infection (CD4 cell count 500 cells/ L), but 
caution that patients should be willing to commit to lifelong 
treatment and should understand the importance of 
adherence [8]. In this large sample of HIV-infected patients 
in the United States, the use of ART was high, but adherence 
to ART was suboptimal. The determinants of nonadherence 
to dose, schedule, and instruction varied, although younger 
age and binge drinking were associated with all three 
measures. Our results support the need to measure multiple 
dimensions of medication-taking behavior, because focusing 
on nonadherence to dose may overestimate adherence to 
ART. Comprehensive assessment of ART nonadherence 
should include measures of dose, schedule, and instruction, 
because accurate information is crucial for evaluating both 
the effectiveness of ART regimens and interventions 
designed to increase adherence. 
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